Hematology and critical care

Disseminated Intravascular Coagulation

Disseminated intravascular coagulation is an acquired, dynamic syndrome of systemic coagulation activation, consumptive factor depletion, and dysregulated fibrinolysis. Diagnose it from the clinical trigger plus serial global hemostasis testing; treatment priorities are rapid source control, organ support, and phenotype-directed hemostatic therapy.

Clinical question: How should clinicians recognize, confirm, and manage DIC while treating its underlying cause and balancing bleeding against thrombosis?

Updated August 21, 20266 minute readHematology

What matters in practice

DIC is a clinicopathologic syndrome, not an isolated laboratory diagnosis: establish a plausible trigger and interpret platelet count, PT/INR, fibrin-related markers, and fibrinogen together and serially. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Treat the precipitating condition urgently; infection control, obstetric intervention, or trauma hemorrhage control is the primary therapy. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Use platelets, plasma, cryoprecipitate, or fibrinogen-containing products for active bleeding, high bleeding risk, or an invasive procedure—not solely to normalize abnormal coagulation tests. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
DIC can present with microvascular or macrovascular thrombosis as well as bleeding; consider heparin when thrombosis predominates and provide VTE prophylaxis when bleeding risk permits. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
A falling platelet count, rising PT/INR, rising D-dimer or fibrin degradation products, and falling fibrinogen trajectory are more informative than a single value. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Clinical recognition

Recognize DIC as a dynamic syndrome in a high-risk clinical context

The immediate task is to identify the trigger, assess hemorrhagic and thrombotic phenotype, and determine organ involvement.

DIC reflects systemic coagulation activation with thrombin generation, consumption of platelets and coagulation factors, endothelial injury, and dysregulated fibrinolysis. The clinical consequence may be diffuse bleeding, microvascular ischemic organ dysfunction, macrovascular thrombosis, or a mixed phenotype. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Sepsis is the most common precipitant. Other important triggers include shock with multiorgan failure, major trauma or tissue injury, obstetric catastrophes, malignancy, vascular injury, toxic or immunologic reactions, and severe liver dysfunction. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Do not delay treatment of the underlying disorder while awaiting confirmatory testing. In suspected sepsis-associated DIC, timely antimicrobial therapy and source control are central interventions; in trauma or obstetric hemorrhage, prioritize definitive hemorrhage control and resuscitation. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Clinical features supporting DIC: new diffuse oozing from lines or wounds, mucosal bleeding, petechiae or ecchymoses, purpura, acral ischemia, symmetrical peripheral gangrene, venous or arterial thrombosis, oliguria, hypoxemia, altered mental status, or otherwise unexplained organ dysfunction. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
A normal or elevated fibrinogen does not exclude early DIC, particularly in inflammatory states; interpret fibrinogen as a trajectory and in relation to the clinical context. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice ScienceDirectLaboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders
COVID-19-associated coagulopathy may initially be hypercoagulable with elevated fibrinogen and D-dimer but preserved PT and platelet count; secondary infection or clinical deterioration can subsequently lead to DIC. BMJBMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice

Clinical contexts and actions when DIC is suspected. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Context	Immediate concern	Priority action
Sepsis or septic shock	Rapidly evolving coagulopathy with organ dysfunction or bleeding	Obtain serial coagulation studies while initiating antimicrobials, source control, and critical-care support. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Major trauma or hemorrhagic shock	Trauma-induced coagulopathy, hemorrhage, hypothermia, acidosis, hypocalcemia	Control bleeding, use institutional massive-transfusion/coagulation protocol, monitor PT/aPTT, fibrinogen, platelets, and consider viscoelastic testing where available. PubMedPubMedInhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update
Obstetric catastrophe	Abrupt consumptive coagulopathy and major hemorrhage	Expedite obstetric source control and provide targeted hemostatic support for bleeding or procedural need. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Cancer-associated or chronic DIC	Thrombosis may predominate despite abnormal coagulation studies	Treat malignancy when feasible; individualize anticoagulation and blood-component support to active thrombosis or bleeding. BMJBMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice

Diagnostic approach

Confirm probability with serial global hemostasis testing

No single assay rules DIC in or out.

Order a CBC with platelet count, PT/INR, aPTT, fibrinogen, and a fibrin-related marker such as D-dimer or fibrin degradation products when DIC is clinically plausible. Review the peripheral smear for schistocytes and assess hemoglobin and hematocrit for concurrent bleeding or microangiopathic hemolysis. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

The characteristic laboratory pattern is thrombocytopenia, prolonged PT/INR, increased fibrin-related markers, and often hypofibrinogenemia. A diagnosis requires integration of these findings with an established or strongly suspected DIC-associated condition. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Serial testing is essential because DIC evolves rapidly and trends determine management. In critically ill or actively bleeding patients, repeat the panel frequently enough to guide resuscitation and procedural decisions; the supplied sources support serial monitoring but do not specify a universal interval. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedInhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update

Supportive pattern: declining platelet count, prolonged PT and often aPTT, rising D-dimer/FDP, and falling fibrinogen. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
A DIC score incorporating platelets, fibrin marker elevation, PT prolongation, and fibrinogen is used to estimate probability; a score greater than 5 indicates high likelihood of overt DIC in the cited scoring approach. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Exclude or concurrently evaluate alternative explanations for thrombocytopenia and prolonged clotting times, including advanced liver disease, vitamin K deficiency, anticoagulant exposure, thrombotic microangiopathy, heparin-induced thrombocytopenia, and acquired factor inhibitors. ScienceDirect+1ScienceDirectLaboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders PubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf

Core testing and interpretation in suspected DIC. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Test	DIC-compatible finding	Clinical use
Platelet count	Declining count or thrombocytopenia	Tracks consumption and informs bleeding/procedural support decisions. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
PT/INR and aPTT	PT prolongation; aPTT may also be prolonged	Assesses consumptive factor depletion and trends response to treatment. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
D-dimer or fibrin degradation products	Elevated	Supports systemic fibrin formation and breakdown but is not specific for DIC. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Fibrinogen	Low or falling	Identifies consumptive hypofibrinogenemia; an initially normal or high value may occur with inflammation. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice ScienceDirectLaboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders
Peripheral smear	Schistocytes may be present	Supports consumptive/microangiopathic process and helps assess competing diagnoses. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Interpretation pitfalls

PT/aPTT prolongation alone does not establish bleeding risk or DIC. Lupus anticoagulant can prolong aPTT without a bleeding phenotype, and anticoagulants, preanalytic problems, inflammation, liver disease, and vitamin K deficiency can confound screening studies. PubMedPubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf

In cirrhosis, abnormal conventional coagulation tests coexist with a rebalanced but unstable hemostatic state; cirrhosis can confer both bleeding and thrombosis risk. Do not diagnose DIC solely from chronic thrombocytopenia and prolonged PT/INR without a compatible acute change or precipitating syndrome. ScienceDirect+1ScienceDirectGuidelines for the management of coagulation disorders in patients with cirrhosis PubMedAGA Clinical Practice Update: Coagulation in Cirrhosis

Role of viscoelastic testing

Viscoelastic assays can provide rapid whole-blood assessment and may help direct transfusion in severely bleeding trauma patients, but their diagnostic thresholds and results are platform-specific. They complement rather than replace conventional tests, clinical assessment, and source control. PubMedPubMedInhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update

Management

Treat the trigger and support hemostasis according to bleeding and thrombosis phenotype

Correcting laboratory abnormalities without treating the driver does not reverse DIC.

Management has three concurrent components: definitive treatment of the precipitating disorder, critical-care support for organ dysfunction, and selective correction of hemostatic deficits when bleeding, a high bleeding risk, or an invasive procedure justifies it. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Avoid reflex transfusion for isolated abnormal coagulation results in a nonbleeding patient. Plasma and platelet transfusions carry harms and should be tied to a clinical hemostatic objective rather than laboratory normalization alone. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

DIC frequently coexists with thrombosis risk. In patients without active bleeding, pharmacologic VTE prophylaxis with heparin or low-molecular-weight heparin is supported by the cited review; therapeutic heparin may be considered when extensive thrombosis predominates. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Escalate care for active major bleeding, shock, progressive organ dysfunction, suspected catastrophic thrombosis, or need for emergent invasive control of the underlying process. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Coordinate hematology, critical care, transfusion medicine, and the specialty managing the precipitant when DIC is severe, atypical, refractory, or complicated by thrombosis. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Monitor clinical bleeding, perfusion, organ function, platelet count, PT/INR, aPTT, fibrinogen, and fibrin-related markers during active management. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Phenotype-directed supportive management in DIC. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Clinical phenotype	Hemostatic strategy	Key limitation
Active bleeding or urgent invasive procedure	Use platelets, plasma, and fibrinogen-containing support selectively according to cytopenia, factor depletion, fibrinogen, and procedural need. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI	Supportive products do not replace source control or treatment of the underlying disease. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
No bleeding and no planned procedure	Avoid routine correction of abnormal coagulation tests with blood components. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI	Continue serial assessment because phenotype can change rapidly. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Predominant thrombosis	Consider therapeutic heparin after assessing bleeding risk and the reversibility of the precipitating process. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI	Evidence is limited; individualize with specialty input. BMJBMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment \| BMJ Best Practice
High VTE risk without active bleeding	Consider pharmacologic thromboprophylaxis with heparin or LMWH. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI	Withhold or modify if bleeding risk becomes unacceptable. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Blood-component and factor support

For active bleeding, high bleeding risk, or an invasive procedure, platelet transfusion may be considered. The cited source describes platelet thresholds commonly used in DIC of less than 50 × 10^9/L in active hemorrhage and 10–20 × 10^9/L for nonbleeding patients considered at high bleeding risk. These are practice thresholds from a review, not a substitute for an institution-specific transfusion protocol. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Fresh frozen plasma can replenish multiple depleted coagulation factors when bleeding or a procedure is present; the cited review describes 15–30 mL/kg. Cryoprecipitate may be used to replenish fibrinogen. Use the smallest effective product exposure and reassess clinically and with repeat testing. PubMedPubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

In hemorrhagic trauma, current international guidance emphasizes early coagulation testing, avoidance of hypothermia, acidosis, and hypocalcemia, and use of viscoelastic-guided treatment where available. That guideline recommends fibrinogen 3–6 g or 30–60 mg/kg for life-threatening hemorrhage or shock, but this is trauma-specific guidance and should not be generalized to all DIC etiologies. PubMedPubMedInhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update

Do not use plasma, platelets, or cryoprecipitate simply to correct asymptomatic laboratory abnormalities. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Address aggravating conditions: hypothermia, acidosis, hypocalcemia, ongoing shock, and dilution from excessive crystalloid resuscitation can worsen coagulopathy. PubMedPubMedInhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update
For warfarin-associated major bleeding that may coexist with or mimic DIC, four-factor PCC plus slow IV vitamin K is recommended by CHEST; this is anticoagulant reversal, not primary treatment of DIC. PubMedPubMedEvidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines - PMC

Anticoagulation when thrombosis predominates

Consider therapeutic heparin when clinically important thrombosis predominates, such as extensive venous or arterial thrombosis, and bleeding is controlled or acceptably low. The decision is individualized because evidence is limited and the risk of hemorrhage can change quickly. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

For hospitalized patients with DIC who are not actively bleeding, prophylactic-dose unfractionated heparin or low-molecular-weight heparin should be considered to reduce VTE risk. Renal impairment affects low-molecular-weight heparin dosing; the cited CHEST guidance suggests dose reduction for therapeutic LMWH when creatinine clearance is less than 30 mL/min. PubMed+1PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI PubMedEvidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines - PMC

Differential and special situations

Distinguish DIC from other coagulopathies that change management

The central diagnostic question is whether the laboratory pattern reflects systemic consumption from an acute trigger.

Liver disease and DIC frequently overlap clinically and biochemically. Cirrhosis produces a rebalanced hemostatic state with concurrent bleeding and thrombotic risk, so prolonged PT/INR and thrombocytopenia do not independently prove DIC. An acute compatible trigger, dynamic deterioration in platelets and fibrinogen, increasing fibrin-related markers, and new organ dysfunction increase concern for superimposed DIC. ScienceDirect+1ScienceDirectGuidelines for the management of coagulation disorders in patients with cirrhosis PubMedAGA Clinical Practice Update: Coagulation in Cirrhosis

A markedly prolonged aPTT without bleeding should prompt consideration of lupus anticoagulant or contact-factor deficiency rather than empiric plasma transfusion. Mixing studies help differentiate factor deficiency from an inhibitor: correction supports deficiency, while failure to correct suggests an inhibitor; time-dependent factor VIII inhibitors may correct initially then prolong after incubation. PubMedPubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf

Anticoagulant exposure can confound coagulation assays and cause bleeding independent of DIC. Establish medication history, timing of last dose, renal function, and relevant drug-specific testing where available. For DOAC-associated emergency bleeding, normal PT/aPTT does not reliably exclude clinically meaningful drug levels. PubMed+1PubMed2025 Guidelines for direct oral anticoagulants - PMC PubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf

Consider thrombotic microangiopathy when thrombocytopenia and schistocytes are prominent; DIC is more likely to show substantial fibrin-related marker elevation and consumptive PT/fibrinogen abnormalities in the appropriate trigger context. PubMed+1PubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Consider heparin-induced thrombocytopenia when thrombosis and platelet fall occur after heparin exposure; use clinical pretest assessment such as the 4Ts score before laboratory testing. PubMedPubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf
Consider acquired hemophilia in unexplained severe soft-tissue bleeding with isolated prolonged aPTT and inhibitor-pattern mixing study. PubMedPubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf

Selected disorders that can resemble DIC. ScienceDirect+3ScienceDirectGuidelines for the management of coagulation disorders in patients with cirrhosis PubMedAGA Clinical Practice Update: Coagulation in Cirrhosis PubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI
Condition	Clue favoring alternative diagnosis	Management consequence
Cirrhosis-associated coagulopathy	Chronic liver disease with abnormal PT/INR and thrombocytopenia but no acute consumptive trajectory	Avoid treating INR alone as a bleeding-risk surrogate; assess clinical bleeding and procedure-specific risk. ScienceDirect+1ScienceDirectGuidelines for the management of coagulation disorders in patients with cirrhosis PubMedAGA Clinical Practice Update: Coagulation in Cirrhosis
Lupus anticoagulant	Prolonged aPTT without bleeding; inhibitor pattern on mixing study	Do not assume factor depletion or give plasma solely for aPTT prolongation. PubMedPubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf
Acquired factor inhibitor	Bleeding with isolated prolonged aPTT that fails to correct or prolongs after incubation	Obtain factor assays and inhibitor testing; pursue hematology-directed therapy. PubMedPubMedLaboratory Evaluation of Coagulopathies - StatPearls - NCBI Bookshelf
Anticoagulant effect	Exposure history, renal dysfunction, or drug-specific level supports anticoagulant accumulation	Use agent-specific reversal and supportive management when indicated. PubMed+1PubMedEvidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines - PMC PubMed2025 Guidelines for direct oral anticoagulants - PMC

Common questions

Can DIC be diagnosed from an elevated D-dimer alone?

No. D-dimer is sensitive to fibrin formation and breakdown but is nonspecific. Diagnose DIC from a compatible underlying condition plus the integrated pattern of platelet trend, PT/INR, fibrin-related marker elevation, fibrinogen, and clinical phenotype. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Should all patients with DIC receive fresh frozen plasma?

No. Plasma is generally reserved for active bleeding, high bleeding risk, or an invasive procedure in the setting of factor depletion. Routine plasma to normalize tests in a nonbleeding patient is not recommended. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

Does a normal fibrinogen exclude DIC?

No. Fibrinogen can remain normal or high early in inflammatory states because it is an acute-phase reactant. A falling fibrinogen trend with worsening thrombocytopenia, PT prolongation, and D-dimer elevation is more informative. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice ScienceDirectLaboratory diagnosis of congenital and acquired coagulopathies, including challenging-to-diagnose rare bleeding disorders

When is heparin appropriate in DIC?

Consider therapeutic heparin when clinically significant thrombosis predominates and bleeding risk is acceptable. In patients without active bleeding, pharmacologic VTE prophylaxis with heparin or LMWH should be considered. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedDisseminated Intravascular Coagulation - StatPearls - NCBI

How often should coagulation studies be repeated in active DIC?

Repeat studies serially often enough to guide active bleeding management, procedures, and response to treatment. The supplied sources endorse serial monitoring but do not provide one universal interval; acuity and rate of clinical change should determine frequency. BMJ+1BMJDisseminated intravascular coagulation - Symptoms, diagnosis and treatment | BMJ Best Practice PubMedInhospital coagulation management and fluid replacement therapy in patients with multiple and/or severe injuries – a systematic review and clinical practice guideline update